Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Confirms Purchase of True Materials

NEW YORK (GenomeWeb News) – Affymetrix has confirmed that the unnamed company that it said last week that it had acquired is True Materials, a microparticle technology firm based in the University of California, San Francisco, Mission Bay Campus.
 
An Affymetrix spokesperson told GenomeWeb Daily News via e-mail that True Materials founder Randy True has joined Affy as a vice president of research and development.
 
True Materials is developing a digitally encoded microparticle technology that will enable the array manufacturer to enter low to mid-multiplex markets and compete with bead-based platforms. Affy said that the technology is also applicable to the research, applied, and diagnostic markets.
 
Affy disclosed the acquisition during its second-quarter conference call last week. Steve Fodor, chairman and CEO of the firm, said the technology "is more scalable and cost effective than bead-based approaches." It uses digital microparticles to carry out assays in solution, he said, and is "capable of multiplexing tests ranging up to several thousand markers."
 

The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.